immunodefici
centromer
instabl
facial
anomali
icf
syndrom
rare
autosom
recess
genet
condit
sever
immunodefici
lead
lethal
infect
recogn
treat
earli
childhood
uptod
treatment
regimen
consist
prophylact
support
treatment
recurr
infect
report
case
boy
moroccan
consanguin
parent
diagnos
month
age
icf
syndrom
homozyg
missens
mutat
gene
initi
admit
hospit
recurr
pulmonari
infect
opportunist
pathogen
pneumocysti
jirovecii
pj
immunolog
workup
reveal
agammaglobulinemia
presenc
b
cell
success
recoveri
pj
pneumonia
underw
hematopoiet
stem
cell
transplant
hsct
hlamatch
healthi
sister
use
chemotherapeut
condit
regimen
consist
treosulfan
fludarabin
thiotepa
acut
chemotherapyassoci
side
effect
seriou
advers
event
occur
six
month
hsct
immunereconstitut
stabl
chimer
autolog
portion
peripher
blood
normal
differenti
blood
cell
count
includ
immunoglobulin
subtyp
one
first
case
success
hsct
icf
syndrom
earli
diagnosi
subsequ
hsct
prevent
sever
opportunist
infect
cure
immunodefici
centromer
instabl
facial
anomali
remain
unaffect
although
longterm
patient
outcom
neurolog
develop
remain
seen
cur
therapi
immunodefici
improv
life
expect
qualiti
life
case
meant
rais
physician
awar
icf
syndrom
highlight
consider
hsct
icf
syndrom
earli
immunodefici
centromer
instabl
facial
anomali
icf
syndrom
rare
autosom
recess
genet
condit
sever
immunodefici
lead
lethal
infect
recogn
treat
earli
childhood
uptod
treatment
regimen
consist
prophylact
support
treatment
recurr
infect
report
case
boy
moroccan
consanguin
parent
diagnos
month
age
icf
syndrom
homozyg
missens
mutat
gene
initi
admit
hospit
recurr
pulmonari
infect
opportunist
pathogen
pneumocysti
jirovecii
pj
immunolog
workup
reveal
agammaglobulinemia
presenc
b
cell
success
recoveri
pj
pneumonia
underw
hematopoiet
stem
cell
transplant
hsct
hlamatch
healthi
sister
use
chemotherapeut
condit
regimen
consist
treosulfan
fludarabin
thiotepa
acut
chemotherapyassoci
side
effect
seriou
advers
event
occur
six
month
hsct
immunereconstitut
stabl
chimer
autolog
portion
peripher
blood
normal
differenti
blood
cell
count
includ
immunoglobulin
subtyp
one
first
case
success
hsct
icf
syndrom
earli
diagnosi
subsequ
hsct
prevent
sever
opportunist
infect
cure
immunodefici
centromer
instabl
facial
anomali
remain
unaffect
although
longterm
patient
outcom
neurolog
develop
remain
seen
cur
therapi
immunodefici
improv
life
expect
qualiti
life
case
meant
rais
physician
awar
icf
syndrom
highlight
consider
hsct
icf
syndrom
earli
immunodefici
centromer
instabl
facial
anomali
icf
syndrom
rare
autosom
recess
inherit
genet
condit
major
affect
individu
mutat
methyltransferas
gene
omim
chromosom
lead
reduc
dna
methyl
pericentromer
region
chromosom
epigenet
dysregul
rather
singl
gene
defect
determin
clinic
phenotyp
although
bodi
cell
carri
mutat
variou
tissu
differ
affect
due
vari
degre
dna
methyl
especi
seen
mitogenstimul
lymphocyt
whole
arm
delet
transloc
multibranch
chromosom
caus
abnorm
gene
regul
b
cell
immunoglobulin
isotyp
switch
lymphocyt
activ
migrat
icf
patient
suffer
recurr
gastrointestin
pulmonari
infect
earli
childhood
due
agammablobulinemia
result
failur
thrive
intrins
cell
defect
also
link
high
frequenc
opportunist
infect
pathogen
pneumocysti
jirovecii
pj
exact
mechan
elucid
typic
clinic
characterist
includ
eponym
facial
anomali
epicanth
fold
hypertelor
flat
nasal
bridg
well
delay
psycholog
cognit
develop
treatment
option
limit
consist
primarili
support
therapi
substitut
immunoglobulin
prophylact
sulfamethoxazoletrimethoprim
therapi
antibiot
therapi
life
expect
icf
patient
poor
prognosi
depend
frequenc
sever
infect
high
proport
report
icf
patient
die
young
age
earli
igg
replac
antibiot
prophylaxi
significantli
improv
patient
outcom
earli
sustain
therapi
immunodefici
dramat
better
diseas
cours
cur
treatment
immun
dysfunct
hematopoiet
stem
cell
transplant
hsct
describ
isol
case
studi
howev
longterm
followup
data
avail
date
report
case
boy
moroccan
consanguin
descent
diagnos
icf
syndrom
carri
homozyg
missens
mutat
gene
hypogammagobulinemia
normal
b
cell
count
facial
anomali
failur
thrive
variant
previous
describ
icf
syndrom
hansen
et
al
consist
point
mutat
amino
acid
exchang
alanin
threonin
variant
minor
allel
frequenc
preval
less
hansen
et
al
describ
variant
among
mutat
gene
control
dna
unrel
healthi
caucasian
north
america
netherland
carri
mutat
boy
born
bodi
weight
g
percentil
length
cm
percentil
cdcwho
growth
chart
age
month
bodi
weight
g
percentil
length
cm
percentil
cdcwho
growth
chart
age
month
patient
admit
hospit
first
time
recurr
prolong
respiratori
infect
lower
upper
airway
hypoxemia
laboratori
workup
reveal
bilater
bronchopneumonia
posit
parainfluenza
viru
type
pj
well
purul
conjunct
purul
otiti
media
perforan
posit
haemophilu
influenza
subsequ
immunolog
diagnost
significantli
reduc
level
immunoglobulin
subclass
tabl
normal
b
cell
count
lack
memori
b
cell
detect
cell
count
prolifer
rate
cell
mitogen
stimul
phytohemagglutinin
normal
bronchoscopi
reveal
normal
anatom
proport
airway
pj
pneumonia
treat
intraven
cotrimoxazol
corticosteroid
oxygen
supplement
subsequ
regular
intraven
immunoglobulin
treatment
prophylact
cotrimoxazol
prevent
sever
pulmonari
infect
addit
patient
typic
facial
dysmorph
consist
hypertelor
flat
nasal
bridg
epicanth
fold
low
set
ear
figur
pictur
face
icf
syndrom
clinic
suspect
confirm
cytogenet
analysi
reveal
whole
arm
delet
transloc
multibranch
chromosom
due
centromer
instabl
chromosom
figur
patient
fifth
child
consanguin
moroccan
parent
first
cousin
figur
three
healthi
older
sibl
old
develop
normal
icf
sibl
exclud
normal
blood
level
immunoglobulin
normal
karyogram
oldest
daughter
famili
die
respiratori
failur
age
month
morocco
genet
patholog
diagnost
perform
post
mortem
age
month
present
bodi
weight
g
percentil
length
cm
percentil
failur
thrive
diagnos
cdcwho
growth
chart
age
month
patient
underw
hematolog
stem
cell
transplant
healthi
sister
hla
match
donor
condit
regimen
consist
thiotepa
treosulfan
fludarabin
receiv
cell
cellskg
bodyweight
cyclosporin
methotrex
antithymocyt
globulin
given
prophylaxi
graftversushost
diseas
gvhd
figur
patient
icf
syndrom
often
display
residu
cell
function
may
result
graft
failur
reject
therefor
subject
reduc
intens
condit
given
good
perform
statu
patient
myeloabl
condit
reduc
toxic
administ
order
achiev
stabl
lymphohematopoiet
engraft
low
risk
organ
toxic
suffer
acut
chemotherapeut
reaction
mucosa
toxic
grade
skin
toxic
grade
nausea
vomit
grade
renal
clearanc
impair
toxic
grade
time
recov
complet
side
effect
leukocyt
neutrophil
engraft
achiev
day
day
respect
chimer
analysi
blood
show
autolog
portion
maximum
chimer
bone
marrow
complet
donor
without
infect
sign
gvhd
discharg
hospit
day
continu
receiv
cyclosporin
day
stepwis
reduc
absenc
sign
gvhd
three
month
transplant
admit
hospit
rsv
infect
success
treat
ribavirin
four
month
posttransplant
admit
due
diarrhea
obstruct
bronchiti
fever
antibiot
treatment
start
initi
discontinu
influenza
rsv
corona
viru
detect
throat
without
specif
antivir
therapi
recov
complet
five
month
transplant
present
diarrhea
subfebril
temperatur
partial
compens
metabol
acidosi
rotaviru
detect
stool
ivfluid
therapi
outpati
suffici
normal
blood
gase
symptom
reced
spontan
six
month
transplant
adenoviru
detect
blood
stool
throat
without
clinic
symptom
intranven
treatment
cidofovir
start
viru
clear
suffici
differenti
blood
count
increas
steadili
normal
month
transplant
tabl
chimer
bone
marrow
show
overal
autolog
portion
fraction
well
subset
chimer
blood
autolog
cell
stabl
last
month
year
age
neurolog
develop
correl
approxim
child
bodi
weight
g
percentil
length
cm
percentil
cdcwho
growth
chart
report
success
allogen
hsct
boy
syndrom
carri
homozyg
mutat
gene
receipt
bone
marrow
cell
hlamatch
clinic
healthi
sister
followup
observ
complet
immun
reconstitut
without
acut
shortterm
transplantationrel
complic
immunodefici
centromer
instabl
facial
anomali
syndrom
rare
sever
immunodefici
diseas
patient
fifth
child
consanguin
parent
underw
hsct
earli
age
month
first
daughter
parent
die
month
age
morocco
due
respiratori
failur
unknown
origin
sinc
diagnost
conduct
post
mortem
specul
homozyg
mutat
gene
might
caus
earli
death
gender
bia
syndrom
caus
mutat
gene
observ
recent
syndrom
affect
gender
equal
make
even
plausibl
deceas
daughter
genet
defect
patient
famili
histori
emphas
fact
icf
patient
poor
clinic
outcom
treat
earli
adequ
case
report
patient
ig
therapi
surviv
childhood
other
die
within
first
year
life
opportunist
infect
describ
nine
icf
case
franc
recent
genneri
et
al
publish
success
cure
immunodefici
hsct
three
icf
patient
receiv
hsct
age
month
year
report
anoth
case
success
hsct
icf
syndrom
receiv
hsct
month
age
hsct
associ
high
risk
mortal
due
shortterm
opportunist
infect
gvhd
longterm
side
effect
includ
chemotherapeut
toxic
liver
kidney
dysfunct
growth
retard
infertil
secondari
malign
patient
never
receiv
chemotherapeut
treatment
beforehand
usual
better
clinic
outcom
transplant
success
acut
side
effect
seen
patient
hemoglobinopathi
sicklecel
anemia
sinc
sever
infect
significantli
worsen
patient
outcom
hsct
aim
perform
hsct
icf
syndrom
earli
possibl
infectionfre
period
icf
syndrom
invari
associ
low
absent
level
immunoglobulin
given
defect
peripher
termin
b
cell
differenti
inde
could
treat
lifelong
igg
replac
howev
number
patient
also
display
function
cell
immunodefici
evidenc
case
pj
pneumonia
furthermor
recent
studi
rechavi
et
al
weema
et
al
highlight
fact
cell
prolifer
defect
develop
time
patient
icf
syndrom
suffer
multisystem
diseas
lead
longterm
morbid
substanti
mortal
usual
stem
sever
infect
ie
gi
tract
associ
growth
retard
limit
life
expect
particularli
advanc
stage
diseas
hsct
associ
higher
risk
mortal
due
preexist
infect
allogen
hsct
therefor
attract
therapeut
approach
patient
sign
cell
immunodefici
without
sever
preexist
morbid
usual
recommend
hlamatch
donor
identifi
although
condit
chemotherapi
accompani
high
toxic
believ
advantag
hsct
significantli
outweigh
natur
diseas
cours
icf
hsct
replac
hematopoiet
cell
carri
mutat
therebi
cure
immunodefici
icf
patient
weema
et
al
hagleitn
et
al
examin
clinic
featur
patient
help
predict
clinic
outcom
hsct
recurr
infect
higher
risk
hematooncolog
malign
elimin
patient
hsct
delay
neurolog
develop
cortic
atrophi
seizur
featur
remain
immunosuppress
treatment
reconstitut
adapt
immun
system
patient
suffer
recurr
respiratori
gastrointestin
infect
attribut
posttransplant
immunosuppress
expect
improv
time
failur
thrive
attribut
high
frequenc
infect
expect
patient
catch
weight
gain
within
come
month
dna
methyl
dynam
process
epigenet
regul
gene
express
develop
process
age
cancerogenesi
cell
differenti
mutat
describ
lead
alter
epigenet
modif
gene
regul
develop
neurogenesi
immun
function
sinc
dna
methyltransferas
intracellular
enzym
secret
taken
surround
tissu
hsct
abl
compens
enzym
defici
cell
type
bodi
recent
studi
show
next
hypomethyl
pericentromer
region
chromosom
global
loss
methyl
icf
patient
fibroblast
lymphoblastoid
cell
lineag
lead
significantli
upregul
gene
express
differenti
methyl
posit
although
region
identifi
remain
unclear
degre
given
tissu
affect
hypomethyl
extent
pattern
chang
develop
question
need
answer
abl
translat
molecular
find
clinic
phenotyp
nevertheless
specul
overact
gene
express
might
great
impact
gene
highli
epigenet
regul
respons
neurolog
develop
germ
line
gene
import
prevent
cancer
develop
still
lead
delay
neurolog
develop
higher
risk
malign
icf
patient
even
success
hsct
see
combin
mild
facial
abnorm
agammaglobulinemia
presenc
normal
b
cell
count
opportunist
infect
patient
physician
must
consid
icf
syndrom
differenti
diagnosi
hsct
cur
treatment
option
immun
defect
carri
earli
improv
surviv
howev
development
neurolog
outcom
remain
larg
unchang
sinc
epigenet
dysregul
nonhematopoet
cell
correct
hsct
studi
approv
local
ethic
committe
carri
accord
declar
helsinki
parent
provid
written
inform
consent
publish
report
pictur
appear
figur
kg
first
draft
manuscript
cs
uf
contribut
we
analysi
ab
fb
fs
gk
rm
care
child
jdd
dw
perform
cytogenet
analysi
ab
care
child
critic
revis
manuscript
import
intellectu
content
mk
care
child
design
supervis
project
critic
review
revis
manuscript
import
intellectu
content
author
approv
final
manuscript
submit
author
thank
patient
famili
